US · ATRC
AtriCure, Inc.
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Mason, OH 45040
- Website
- atricure.com
Price · as of 2025-12-31
$29.02
Market cap 1.56B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $46.55 | +60.41% |
| Intrinsic Value(DCF) | $21.25 | -26.77% |
| Graham-Dodd Method(GD) | $3.18 | -89.04% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $10.40 | $176.89 | $0.07 | $0.00 | $0.00 |
| 2012 | $8.34 | $29.79 | $0.00 | $0.00 | $0.00 |
| 2013 | $20.39 | $37.88 | $8.72 | $0.00 | $0.00 |
| 2014 | $19.73 | $47.89 | $50.55 | $0.61 | $0.00 |
| 2015 | $18.87 | $42.87 | $35.35 | $0.00 | $0.00 |
| 2016 | $18.32 | $28.49 | $30.77 | $0.00 | $0.00 |
| 2017 | $19.65 | $37.24 | $20.84 | $0.00 | $0.00 |
| 2018 | $29.00 | $44.25 | $27.39 | $1.13 | $0.00 |
| 2019 | $36.97 | $42.08 | $5.46 | $0.00 | $0.00 |
| 2020 | $65.81 | $47.28 | $3.06 | $0.00 | $2.30 |
| 2021 | $59.70 | $65.88 | $3.89 | $11.09 | $44.00 |
| 2022 | $35.87 | $39.58 | $0.00 | $0.00 | $0.00 |
| 2023 | $36.15 | $61.77 | $35.20 | $1.71 | $0.00 |
| 2024 | $34.52 | $42.55 | $23.06 | $0.06 | $0.00 |
| 2025 | $30.93 | $46.55 | $32.12 | $3.18 | $0.00 |
AI valuation
Our deep-learning model estimates AtriCure, Inc.'s (ATRC) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $46.55
- Current price
- $29.02
- AI upside
- +60.41%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$21.25
-26.77% upside
Graham-Dodd
$3.18
-89.04% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ATRC | AtriCure, Inc. | $29.02 | 1.56B | +60% | -27% | -89% | — | -129.01 | 3.00 | 2.76 | 86.02 | — | 7.06 | 74.41% | -0.64% | -2.14% | -2.40% | -0.83% | -1.81% | 0.18 | -0.59 | 3.96 | 2.87 | -4.89 | -7474.00% | 1488.00% | -52900.00% | 3.27% | 0.70 | 11.67% | 0.00% | 0.00% | 3.01% | -405.42 | 28.94 | 2.61 | 5.82 |
| AZTA | Azenta, Inc. | $26.98 | 1.24B | +62% | -42% | -40% | — | -28.75 | 0.93 | 2.70 | 25.40 | — | 1.74 | 45.52% | -1.90% | -9.39% | -3.19% | -0.31% | -2.68% | 0.06 | — | 2.98 | 2.23 | -3.12 | -6052.00% | 355.00% | 21029.00% | 2.39% | 0.30 | 2.67% | 0.00% | 0.00% | 0.00% | -121.90 | 35.84 | 2.31 | 4.42 |
| BLFS | BioLife Solutions, Inc. | $24.20 | 1.17B | +49% | -55% | -73% | — | — | 2.89 | 11.18 | -103.07 | — | 2.89 | 64.56% | -12.61% | -12.61% | 0.00% | -4.52% | 0.00% | 0.03 | -4.48 | 5.23 | 5.23 | -1.18 | -4318.00% | 1697.00% | 28653.00% | 1.87% | 0.88 | 7.49% | 0.00% | — | 0.00% | -79.66 | 48.04 | 10.04 | 18.23 |
| IMCR | Immunocore Holdings plc | $32.30 | 1.64B | +113% | -48% | -85% | — | -46.31 | 4.32 | 5.53 | 2128.75 | — | 4.32 | 97.91% | -11.34% | -8.88% | -9.58% | 14.46% | -3.42% | 0.11 | -2.77 | 4.04 | 3.80 | -1095.49 | -4804.00% | 2010.00% | -15893.00% | -0.75% | -0.03 | 5.28% | 0.00% | 0.00% | 24.39% | -24.43 | -66.96 | 2.77 | 1.37 |
| KMTS | KESTRA MEDICAL TECHNOLOGI… | $23.28 | 1.36B | +67% | +283% | — | — | -6.49 | 3.60 | 12.35 | -5.57 | -4.28 | 3.60 | 40.47% | -177.85% | -190.28% | 5732.26% | 132.69% | -66.62% | 0.22 | -13.75 | 6.72 | 6.47 | 1.97 | 15147.00% | 11505.00% | 1941.00% | -13.70% | -2.04 | 126.23% | 0.22% | -1.50% | 31.39% | -5.13 | -5.39 | 9.12 | 2.34 |
| LMAT | LeMaitre Vascular, Inc. | $108.18 | 2.45B | -46% | -51% | -89% | -62% | 41.10 | 5.37 | 8.23 | 25.41 | 93.35 | 7.69 | 68.63% | 23.77% | 20.03% | 13.87% | 18.60% | 9.80% | 0.55 | 254.91 | 13.14 | 10.77 | 2.40 | 4403.00% | 1363.00% | 2603.00% | 2.05% | 1.44 | 17.08% | 0.79% | 32.60% | 0.79% | 32.46 | 45.64 | 7.71 | 6.95 |
| NVCR | NovoCure Limited | $13.67 | 1.53B | +107% | -55% | — | — | -11.06 | 4.43 | 2.30 | -11.25 | — | 4.43 | 74.54% | -23.47% | -20.79% | -38.89% | -119.85% | -13.32% | 0.85 | — | 2.90 | 2.57 | -1.57 | -2179.00% | 828.00% | 932.00% | -5.02% | -0.22 | -58.98% | 0.00% | 0.00% | 22.09% | -8.71 | -17.70 | 2.04 | 0.52 |
| QDEL | QuidelOrtho Corporation | $22.74 | 1.54B | -6% | -60% | — | — | -1.35 | 0.80 | 0.56 | -8.47 | — | -2.38 | 46.67% | -33.67% | -41.45% | -46.15% | -18.22% | -18.56% | 1.46 | -5.18 | 1.50 | 0.64 | -5.40 | -4535.00% | -189.00% | -2596.00% | -5.42% | 0.11 | -1.65% | 0.00% | 0.00% | 0.00% | -4.50 | -49.82 | 1.51 | 0.29 |
| SEM | Select Medical Holdings C… | $14.97 | 1.86B | +47% | -60% | — | +4% | 12.67 | 1.09 | 0.34 | 10.42 | — | -2.45 | 11.54% | 6.14% | 2.68% | 8.63% | 5.42% | 2.55% | 2.17 | 2.85 | 1.04 | 0.90 | 6.93 | -2892.00% | 512.00% | -2908.00% | 20.66% | 0.35 | 7.88% | 1.70% | 21.50% | 7.10% | 16.53 | 14.45 | 1.01 | 1.62 |
| TXG | 10x Genomics, Inc. | $23.05 | 2.94B | +141% | -55% | -80% | — | -66.29 | 3.63 | 4.49 | -22.74 | — | 3.96 | 69.05% | -17.25% | -6.77% | -5.78% | -26.72% | -4.44% | 0.20 | — | 4.46 | 3.95 | 2.85 | -7697.00% | 525.00% | -237116.00% | 4.51% | 0.89 | 31.35% | 0.00% | 0.00% | 1.90% | -22.74 | 19.38 | 3.92 | 5.92 |
| XERS | Xeris Biopharma Holdings,… | $6.12 | 1.02B | +379% | +286% | — | — | -11.35 | -21.01 | 3.06 | -58.75 | — | -4.11 | 81.86% | -16.57% | -27.00% | 301.32% | -20.18% | -16.99% | -9.17 | -1.01 | 1.67 | 1.12 | -14.28 | -1778.00% | 2389.00% | -2321.00% | -6.08% | -0.37 | -23.64% | 0.00% | 0.00% | 0.60% | -24.44 | -21.72 | 4.05 | -1.32 |
About AtriCure, Inc.
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
- CEO
- Michael H. Carrel
- Employees
- 1.3K
- Beta
- 1.41
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($21.25 ÷ $29.02) − 1 = -26.77% (DCF, example).